

## **HYTN Lists on the OTC Pink Market**

Vancouver, British Columbia – July 29th, 2024 - HYTN Innovations Inc. (CSE: HYTN | FSE: 85W0 | OTC PINK: HYTNF) “HYTN” or “the Company”, a pharmaceutical company specializing in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds, including cannabis and psilocybin, is pleased to announce its approval for trading on the OTC PINK Market (“OTC PINK”) effective July 29th, 2024, under the trading symbol “HYTNF”.

Elliot McKerr, HYTN Chief Executive Officer, commented, “As HYTN begins trading on the OTC market, the Company is thrilled to enhance its visibility and accessibility to a wider range of investors. This milestone underscores HYTN's dedication to sustained growth and value creation, aligning with the organizations long-term strategic goals.”

The Company notes that its common shares will continue to trade on the Canadian Securities Exchange (“CSE”) under the symbol HYTN and the Frankfurt Stock Exchange (“FSE”) under the symbol 85W0.

About HYTN Innovations Inc.

HYTN Innovations Inc. is a pharmaceutical company that specializes in the formulation, manufacturing, marketing, and sale of products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids and psilocybe-derived tryptamines. HYTN is dedicated to becoming a premier provider of these products across all federally regulated markets. The Company accomplishes this by strategically identifying market opportunities and effectively bringing innovative products to market through its advanced development platform.

For more information contact:

Elliot McKerr  
Chief Executive Officer  
1.866.590.9289

HYTN Investor Relations:  
1.866.590.9289  
[investments@hytn.life](mailto:investments@hytn.life)

The Canadian Securities Exchange (CSE) has not reviewed, approved, or disapproved the contents of this press release.

*Certain information contained herein may constitute forward-looking statements that involve risks and uncertainties. Readers are cautioned not to place undue reliance on forward-looking statements, including but not limited to statements regarding: (i) the Company trading on the OTC PINK market. (ii) the Company enhancing its visibility to a wider range of investors. (iii) the Company's common shares continuing to trade on the CSE and FSE. Factors that could cause actual results to vary from forward-looking statements or may affect the operations, performance, development, and results of the Company's business include, among other things: the Company's failure to generate sufficient cash flow from operations to meet its current and future obligations; the Company's failure to access sources of debt and equity capital; changes to the regulatory framework within which the Company operates; competitive factors, pricing pressures, and supply and demand in the Company's industry; and general economic and business conditions. Any statements that are not statements of historical fact are deemed to be forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and, except to the extent required by applicable law, the Company assumes no obligation to update or revise forward-looking statements made herein or otherwise, whether because of new information, future events, or otherwise. The forward-looking statements contained in this news release are expressly qualified by this cautionary note.*